Pliant Therapeutics Q1 net loss narrows on lower expenses

Pliant Therapeutics

11/05/2026 22:10

Overview

U.S. biopharma firm's Q1 net loss narrowed from prior year on lower operating expenses

Company dosed first participant in FORTIFY Phase 1b trial of PLN-101095 in April

Updated Phase 1 data for PLN-101095 showed deepening responses in checkpoint inhibitor-refractory tumors

Outlook

Company expects interim data from FORTIFY Phase 1b trial in 2027

Pliant expects cash resources to fund operations into second half of 2028

Company continues preclinical studies for integrin-targeted drug delivery platform

Result Drivers

CLINICAL TRIAL PROGRESS - Co initiated FORTIFY Phase 1b trial of PLN-101095 ahead of schedule and dosed first participant in April

UPDATED PHASE 1 DATA - Updated Phase 1 trial data for PLN-101095 showed deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors

LOWER OPERATING EXPENSES - Net loss narrowed mainly due to lower research and development and general administrative expenses after completion of prior clinical program and reduced headcount

Company press release: ID:nGNX7w8JJv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.32


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, about 145.9% above its May 8 closing price of $1.22

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)